THU0416 Disease Activity and Safety During Long-Term (104-Week) Treatment with Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 3)
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 348.2-349
◽
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 597.2-598
2016 ◽
Vol 74
(5)
◽
pp. AB248
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 350.2-351
◽
2013 ◽
Vol 72
(Suppl 3)
◽
pp. A163-A163
◽
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 730.2-730
◽
2014 ◽
Vol 70
(5)
◽
pp. AB174
◽
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 732.1-732
◽
2014 ◽
Vol 53
(suppl_1)
◽
pp. i138-i139
◽
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 735.1-735
◽